drugset

drugset / Trial / NCT03533946

Rucaparib in Nonmetastatic prOstAte With BRCAness

NCT03533946 ↗

Phase 2 Terminated 7 enrolled University of Utah Clovis Oncology, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single arm, open label, phase II trial to assess efficacy of rucaparib.

Timeline

Start: 2019-05-20
Primary completion: 2023-01-12
Completion: 2023-01-12

Publications

Sahu KK, Li H, Mathew Thomas V, Benson M, Boucher K, Gupta S, Kohli M, Swami U, Agarwal N, Maughan BL. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR). Oncologist. 2024 May 3;29(5):450-e725. doi: 10.1093/oncolo/oyae030.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rucaparib	Small molecule	600 mg	Oral

Indications